Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells

British Journal of Cancer

Volumn 82, Issue 3, 2000, Pages 691-701

  Selvan, R S ^a,b   Pappas, T N ^a   Ward, F E ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Immune response; Mucin; Pancreatic tumour; T cell; Tumour antigen

Indexed keywords

ALLOANTIGEN; AUTOANTIGEN; CD4 ANTIGEN; HLA ANTIGEN; MUCIN; TUMOR ANTIGEN;

ANTIGEN PRESENTING CELL; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL; TUMOR CELL;

EID: 0033975510     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.1999.0982     Document Type: Article

References (36)

1. Agrawal B, Krantz MJ, Reddish MA and Longenecker B (1998) Cancer-associated MUC1 mucin inhibits human T cell proliferation, which is reversible by IL-2. Nat Med 4: 43-49
2. Barnd DL, Lan MS, Metzgar RS and Finn OJ (1989) Specific, major histocompatibility complex-unrestricted recognition of tumour-associated mucins by cytotoxic T cells. Proc Natl Acad Sci USA 86: 7159-7163
3. Belldegrun A, Kasid A, Uppenkamp M, Topalian SL and Rosenberg SA (1989) Human tumor-infiltrating lymphocytes: analysis of lymphokine mRNA expression and relevance to cancer immunotherapy. J Immunol 142: 4520-4526
4. Bohm CM, Mulder MC, Zennadi R, Notter M, Schmilt-Graft A, Finn OJ, Taylor Papadimitriou J, Stein H, Clausen H, Riecken EO and Hanski C (1997) Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. Scand J Immunol 46: 27-34
5. Borowitz MJ, Tuck FL, Sindelar WF, Fernsten PD and Metzgar RS (1984) Monoclonal antibodies against human pancreatic adenocarcinoma: distribution of DU-PAN-2 antigen on glandular epithelia and adenocarcinoma. J Natl Cancer Inst 72: 999-1005
6. Boussiotis VA, Freeman GJ, Gribben JG, Hayes DF and Nadler LM (1998) No evidence for MUC1-induced apoptosis. Nat Med 4: 1093
7. Chakraborty NG, Twardzik DR, Sivanandham M, Ergin MT, Hellstrom KE and Mukherji B (1990) Autologous melanoma-induced activation of regulatory T cells that suppress cytotoxic response. J Immunol 145: 2359-2364
8. De Plean E, Lurquin C, Lethe B, van der Bruggen P, Brichard V, Renauld JC, Coulie P, Van Pel A and Boon T (1997) Identification of genes coding for tumor antigens recognized by cytolytic T lymphocytes. Methods 12: 125-142
9. Domenech N, Henderson RA and Finn OJ (1995) Identification of an HLA-AH-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J Immunol 155: 4766-4774
10. Gjertsen MK, Saeterdal I, Thorsby E and Gaudernack G (1996) Characterization of immune responses in pancreatic carcinoma patients after mutant p21 ras peptide vaccination. Br J Cancer 74: 1828-1833
11. Goydos JS, Elder E, Whiteside TL, Finn OJ and Lotze MT (1997) A phase I trial of a synthetic mucin peptide vaccine. Induction of specific immune reactivity in patients with adenocarcinoma. J Surg Res 63: 298-304
12. Grem J (1997) The prognostic importance of tumor markers in adenocarcinoma of the gastrointestinal tract. Curr Opin Oncol 9: 380-387
13. Grimm EA, Mazumder A, Zhang HZ and Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823-1841
14. Henderson RA, Nimgaonkar MT, Watkins SC, Robbins PF, Ball ED and Finn OJ (1996) Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen mucin (MUC-1). Cancer Res 56: 3763-3770
15. Jerome KR, Barnd DL, Bendt KM, Boyer CM, Taylor-Papadimitriou J, McKenzie IFC, Bast RC Jr and Finn OJ (1991) Cytotoxic T lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res 51: 2908-2916
16. Katano M, Nagumo F, Kubota E, Yamamoto H, Matsuo T, Hisatsugu T and Tadano J (1993) Autologous tumor-specific cytotoxic T cell clone established from tumor-infiltrating lymphocytes (TIL) of malignant ascites in the absence of recombinant interleukin 2 (rIL-2): activation by autologous tumor cell alone. Biother 6: 25-32
17. Lan MS, Finn OJ, Fernsten PD and Metzgar RS (1985) Isolation and properties of a human pancreatic adenocarcinoma-associated antigen, DU-PAN-2. Cancer Res 45: 305-310
18. Lan MS, Khorrami A, Kaufman B and Metzgar RS (1987) Molecular characterization of a mucin-type antigen associated with human pancreatic cancer. The DU-PAN-2 antigen. J Biol Chem 262: 12863-12870
19. McKolanis J, Pecher G, Lotze M and Finn OJ (1996) Mucin reactive CTL induced by in vivo immunization (Abstr). Proc Am Assoc Cancer Res 87: 3144
20. Magarian-Blander J, Hughey RP, Kinlough C, Poland PA and Finn OJ (1996) Differential expression of MUC1 on transfected cell lines influences its recognition by MUC1 specific T cells. Glycoconjugate J 13: 749-756
21. Magarian-Blander J, Ciborowski P, Hsia S, Watkins SC and Finn OJ (1998) Intercellular and intracellular events following the MHC-unrestricted TCR recognition of a tumor-specific peptide epitope on the epithelial antigen MUC1. J Immunol 160: 3111-3120
22. Metzgar RS, Rodriguez N, Finn OJ, Lan MS, Daasch VN, Fernsten PD, Meyers WC, Sindelar WF, Sandler RS and Seigler HF (1984) Detection of a pancreatic cancer-associated antigen (DU-PAN-2 antigen) in serum and ascites of patients with adenocarcinoma. Proc Natl Acad Sci USA 81: 5242-5246
23. Miller G and Lipman M (1973) Release of infectious Epstein-Barr virus by transformed marmoset leukocytes. Proc Natl Prod USA 70: 190-194
24. Paul S, Bizouarne N, Paul A, Price MR, Hansson GC, Kieny MP and Acres RB (1999) Lack of evidence for an immunosuppressive role for MUC1. Cancer Immunol Immunother 48: 22-28
25. Peiper M, Nagoshi M, Patel D, Fletcher JA, Geogebuure PS and Eberlein TJ (1997a) Human pancreatic cancer cells (MPane-96) recognized by autologous tumor-infiltrating lymphocytes after in vitro as well as in vivo tumor expansion. Int J Cancer 71: 993-999
26. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC and Eberlein TJ (1997b) The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 27: 1115-1123
27. Poland PA, Kinlough CL, Rokaw MD, Magarian-Blander J, Finn OJ and Hughey RP (1997) Differential glycosylation of MUC1 in tumors and transfected epithelial and lymphoblastoid cell lines. Glycoconjugate J 14: 89-96
28. Pollack MS, Heagney SD, Livingston PO and Fogh J (1981) HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J Natl Cancer Inst 66: 1003-1012
29. + T cell immunity to mutated ras protein in pancreatic and colon cancer patients. Cancer Res 55: 2984-2987
30. Robbins PF and Kawakami Y (1996) Human tumor antigens recognized by T cells. Curr Opin Immunol 8: 628-636
31. + T cytotoxic cells. Int J Cancer 45: 1096-1104
32. Selvan RS, Nagarkatti PS and Nagarkatti M (1991) Characterization of T lymphocyte clones isolated from BCNU-cured LSA mice. Int J Cell Cloning 9: 594-605
33. Slovin SF, Lackman RD, Ferrone S, Kiely PE and Mastrangelo MJ (1986) Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol 137: 3042-3048
34. Tan MH, Nowak NJ, Ochi H, Sandberg AA, Lopez C, Pickren JW, Berjian R, Douglass HO and Ming Chu T (1986) Characterization of a new primary pancreatic tumor line. Cancer Invest 4: 15-23
35. Wahab ZA and Metzgar RS (1991) Human cytotoxic lymphocytes reactive with pancreatic adenocarcinoma cells. Pancreas 6: 307-317
36. Wolfel T, Herr W, Coulie P, Schmitt U, Meyer Zum Buschenfelde K-H and Knuth A (1993) Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class 1-restricted cytolytic T-lymphocyte (CTL) clones. Int J Cancer 54: 636-644.